Abstract: This disclosure relates more particularly to risk assessment of autism spectrum disorder (ASD) present in the subject and designing a personalized recommendation for the same. Current diagnostic tools and procedures, though abundant in numbers, are all based on psychiatric or behavioral evaluations, checklists and associated statistical inferences, which highlight the inherent limitation in making a reliable and early diagnosis. The present disclosure makes use of oral microbial samples of both saliva and dental plaque. The present disclosure involves a paired extraction and quantification of site-specific unique microbial sequences pertaining to the oral microbial samples of an ASD subject and subsequent classification of the subject under the ASD risk category using a metric based on a predefined ensemble of mathematical formulas. Further, a guided development of personalized microbial cocktail(s) is then designed based on the most relevant formula-set for the subject.

Abstract: This disclosure relates more particularly to risk assessment of preterm delivery (PTD) in the subject and designing a personalized recommendation for the same. Conventional techniques for PTD risk assessment are either invasive or minimally invasive and leaves little time for subjects to take precautionary or corrective medical advice or procedures to reduce or obviate the risk. The present disclosure provides the risk assessment of the PTD, by quantifying a microbial abundance in oral or gut microbiome for a pregnant woman, identifying a certain combination of microbial biomarkers using an ensemble of models for accurate risk assessment of the PTD and subsequently suggesting a personalized recommendation for at risk subject. The present assessment technique is completely non-invasive and further helps in characterizing the risk of the PTD.

Abstract: The present disclosure is related to method and system for identifying and utilizing frugal markers for classification of biological sample. Discovering an optimal and/or frugal set of features/biomarkers form a large set of features measured through high-throughput screening techniques, which can characterize a disease/anomaly with sufficient accuracy, still remains a challenge. According to the present disclosure, given a set of measurements of multiple features characterizing biological samples obtained from disease cases and healthy controls, a classification model combining the measured values of a small subset of the features is computed. The classification model is then used for classifying between disease cases and healthy controls.

Abstract: Skin-associated autoimmune diseases are common these days. A method and composition for microbiome based amelioration of skin associated autoimmune inflammatory diseases has been provided. The composition is made of at least one or more of microbiome-associated compounds such as proteins, metabolites, antibiotics, probiotics, etc. The method provides a composition for an affected individual through application of these compositions aimed at improving the bioavailability of lipoic acid. It acts through modulation of the lipoic acid metabolic pathway to do the same. The suggested microbes and compounds can either be used as an effective probiotic supplement in increasing the microbial population involved in lipoic acid biosynthesis (only), or increasing the number of competitors of the microbes involved in escalation of lipoic acid salvage system, or through direct antibiotic or physical action against the latter.

Abstract: The need for an accurate, early, and precise estimation of expected delivery date (EDD) for the pregnant subject is vital. A system and method for predicting a day/date of delivery for a pregnant subject using one or more microbiome samples collected from the pregnant subject is provided. The disclosure relates to applying machine learning techniques on the microbiome characterization data corresponding to the biological sample(s) collected from the pregnant subject. The method further comprises using the predicted EDD to suitably plan and take required medical treatment or precautions or medical advice for the pregnant subject to prevent any pregnancy and/or delivery related complications and to manage the delivery appropriately. The disclosure also provides compositions of the microbiome data which can potentially influence the delivery date, or the method provides exemplary compositions of the microbiome data which plays vital role in estimating the EDD of the pregnant subject.

Abstract: Many microbes are capable of synthesizing anti-cancer products, however existing state of art is limited by focus on industrial production of the said products. A method and system for preparing a knowledgebase of microbes and microbial functions to identify good and bad microbes have been provided. The present disclosure therefore further describes methods and compositions for the risk assessment, prevention and management of various forms of cancer by using microbes, microbial products utilizing the knowledgebase of microbes and microbial function. The method is configured to priming the microbes inside the host for boosting the immune response against cancer initiation, progression, recurrence and associated side effects. The use of microbes and microbial products can be provided in the form of probiotics, supplements, and prebiotics etc. along with creation of right sets of nutrition conditions in the host for the proper functioning of the microbes and microbial products.

Abstract: Disclosed are quinoline esters of Formula (I): which are useful as Liver X receptors (LXR) modulators. Pharmaceutical compositions containing quinoline esters of Formula (I) and the use of quinoline esters of Formula (I) in the safe treatment of various skin disorders are also disclosed. Methods for preparing and using quinoline esters are further described.

Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: Disclosed herein are methods of preventing and treating osteoarthritis through the use of RXR agonists.

Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating and psoriasis.

Abstract: Disclosed herein are methods of preventing and treating osteoarthritis through the use of LXR agonists.

Abstract: The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.